Inclusion body myositis in Alzheimer's disease

Acta Neurologica Scandinavica

Volumn 124, Issue 3, 2011, Pages 215-217

  Roos, P M ^a,b   Vesterberg, O ^c   Nordberg, M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Alzheimer's disease; Electroencephalography; Electromyographic; Inclusion body myositis; Metal; Muscle biopsy

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; BRAIN ELECTROPHYSIOLOGY; CASE REPORT; DYSPHAGIA; ELECTROENCEPHALOGRAM; ELECTROMYOGRAPHY; FEMALE; HUMAN; INCLUSION BODY MYOSITIS; MUSCLE BIOPSY; NOTE;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; FEMALE; HUMANS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; MYOSITIS, INCLUSION BODY; TAU PROTEINS;

EID: 79961186180     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01461.x     Document Type: Note

References (12)

1. Lilienfeld DE, Perl DP. Projected neurodegenerative disease mortality in the United States, 1990-2040. Neuroepidemiology 1993;12:219-28.
2. Lobo A, Launer LJ, Fratiglioni L et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54:S4-9.
3. Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement 2010;6:98-103.
4. Murphy MP, Golde TE. Inclusion-body myositis and Alzheimer disease. Two sides of the same coin, or different currencies altogether? Neurology 2006;66(2 Suppl 1):S65-8.
5. Needham M, Corbett A, Day T, Christiansen F, Fabian V, Mastaglia FL. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 2008;15:1350-3.
6. Mendell JR, Sahenk Z, Gales T, Paul L. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch Neurol 1991;48:1229-34.
7. Dong J, Canfield JM, Mehta AK et al. Engineering metal ion coordination to regulate amyloid fibril assembly and toxicity. Proc Natl Acad Sci USA 2007;104:13313-8.
8. Nordberg M, Nordberg GF. Toxicological aspects of metallothionein. Cell Mol Biol (Noisy-le-grand) 2000;46:451-63.
9. Crouch PJ, White AR, Bush AI. The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease. Febs J 2007;274:3775-83.
10. Shcherbatykh I, Carpenter DO. The role of metals in the etiology of Alzheimer's disease. J Alzheimers Dis 2007;11:191-205.
11. Askanas V, Engel WK. Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta Neuropathol 2008;116:583-95.
12. Laferla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007;8:499-509.